Release date: 2014-10-15
In the past few years, 2013 was the most prosperous year for the biotech IPO market, with more than 45 biotech companies conducting IPOs, raising more than $3 billion in funds to support drugs in the pipeline.
In 2014, biotechnology IPOs continued to ignite capital markets. In the first quarter alone, 29 life science companies went public, raising a total of $2.1 billion . By the middle of the year, 2014 has proved to be more favorable than any previous year. Can be figured. However, not all companies are able to successfully raise prospective funds. In the second quarter of this year, market concerns about the pricing of some biotech giants and related regulatory barriers have caused volatility in the industry. This panic has forced some biotech companies to lower IPO prices and raise funds. It has also led many companies to postpone IPO plans.
FierceBiotech conducted a statistical analysis of the 2014 IPO biotechnology company and selected the top 10 biotech companies in the 2014 IPO based on the total amount of funds raised and the IPO performance. The list is as follows:
1. Ultragenyx Pharmaceutical ($RARE)
Headquarters: Novato, California, USA;
IPO issue price: 21 US dollars;
Closing price on September 30: US$56.60;
Change: up 170%;
Raised funds: $122 million
2. ZS Pharma ($ZSPH)
Headquarters: Coppell, Texas, USA;
IPO issue price: 18 US dollars;
Closing price on September 30: US$39.23;
Change: Zhang 118%;
Raised funds: $107 million
3. Auspex Pharmaceuticals ($ASPX)
Headquarters: La Jolla, California, USA;
IPO issue price: 12 US dollars;
Closing price on September 30: $25.67;
Change: up 114%;
Raised funds: $84 million
4. Avalanche Biotechnologies ($AAVL)
Headquarters: Menlo Park, California;
IPO issue price: $17;
Closing price on September 30: $34.19;
Change: up 101%;
Raised funds: $102 million
5. Sage Therapeutics ($SAGE)
Headquarters: Cambridge, Massachusetts, USA;
IPO issue price: 18 US dollars;
Closing price on September 30: US$31.50;
Change: up 75%;
Raised funds: 90 million US dollars
6. Kite Pharma ($KITE)
Headquarters: Cambridge, California;
IPO issue price: $17;
Closing price on September 30: $28.50;
Change: up 68%;
Raised funds: $128 million
7. Otonomy ($OTIC)
Headquarters: San Diego, California, USA;
IPO issue price: $16;
Closing price on September 30: $24;
Change: up 50%;
Raised funds: $100 million
8, Zafgen ($ZFGN)
Headquarters: San Diego, California, USA;
IPO issue price: $16;
Closing price on September 30: $19.65;
Change: up 23%;
Raised funds: $96 million
9, ProQR Therapeutics ($PRQR)
Headquarters: Leiden, The Netherlands;
IPO issue price: 13 US dollars;
Closing price on September 30: $17.19;
Change: up 32%;
Raised funds: $98 million
10. Radius Health ($RDUS)
Headquarters: Waltham, Massachusetts, USA;
IPO issue price: 8 US dollars;
Closing price on September 30: $21;
Change: up 163%;
Raised funds: $52 million
Source: Bio Valley
ZHANGJIAGANG DINSHENGLIN TRADING CO.,LTD , https://www.dslhouse.com